Banking

Stocks Showing Improved Relative Strength: Biogen

On Friday, Biogen (BIIB) earned a positive adjustment to its Relative Strength (RS) Rating, from 69 to 75.

When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This exclusive rating from Investor’s Business Daily measures market leadership with a 1 (worst) to 99 (best) score. The score shows how a stock’s price movement over the last 52 weeks stacks up against all the other stocks in our database.

Decades of market research shows that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Biogen can continue to rebound and hit that benchmark.


See How IBD Helps You Make More Money In Stocks


While the stock is not near a proper buy point right now, see if it manages to form and break out from a proper base.

The company reported negative growth for both sales and earnings last quarter.

The company earns the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. Regeneron Pharmaceutical (REGN) and Maravai Lifesciences (MRVI) are also among the group’s highest-rated stocks.

YOU MIGHT ALSO LIKE:

Biotech And Pharmaceutical Industry And Stock News

Stocks With Rising Relative Strength Ratings

Why Should You Use IBD’s Relative Strength Rating?

How Relative Strength Line Can Help You Judge A Stock

See How To Reduce Risk, Increase Profits With Swing Trading

Most Related Links :
editorpen Governmental News Finance News

Source link

Back to top button